Estrogen receptor ligand treatment for neurodegenerative diseases

Patent metadata

Field	Value
Publication number	US-10758496-B2
Application number	US-201515507881-A
Country	US
Kind code	B2
Filing date	Sep 1, 2015
Priority date	Sep 2, 2014
Publication date	Sep 1, 2020
Grant date	Sep 1, 2020

Abstract

The present invention relates to treatment of neurological diseases such as multiple sclerosis (MS) and Alzheimer's disease, using an estrogen receptor beta (ERβ) ligand.

First claim

What is claimed is:

1. A method of slowing cerebral cortex gray matter atrophy in a subject suffering from multiple sclerosis, comprising administering to the subject an estrogen receptor beta ligand and evaluating the subject's brain gray matter.

2. The method of claim 1 , wherein the subject has greater than about 0.1%, about 0.2%, or about 0.3%, or about 0.4%, or about 0.5%, or about 0.6%, or about 0.7%, or about 0.8%, or about 0.9%, or about 1.0%, or about 1.1%, or about 1.2%, or about 1.3%, or about 1.4%, or about 1.5%, or about 2.0% brain gray matter atrophy per annum.

3. The method of claim 2 , wherein evaluating the subject's gray matter comprises using an imaging technique selected from magnetic resonance imaging (MRI), fast fluid-attenuated inversion recovery (FLAIR), double inversion recovery (DIR), phase-sensitive inversion recovery (PSIR), ultra high-field MRI, magnetization transfer imaging (MTI), T1-relaxometry, diffusion tensor imaging (DTI), proton magnetic resonance spectroscopy (MRS)), and related techniques and combinations thereof, or surrogate marker selected from one or more of nogo receptor, kallikrein-6 (neurosin), cerebellin-1, ceruloplasmin, dickkopf-3 (rig-like 7-1), amyloid beta precursor-like protein 1, activated leukocyte cell adhesion molecule (CD166), neural cell adhesion molecule 2, neural epidermal growth factor like 2/cerebral protein-12, clusterin (apolipoprotein j, complement lysis inhibitor), brevican, neuronal cadherin, chitinase-3-like 1 protein, neogenin, multifunctional protein MFP (collagen alpha 1 (XVIII) chain; endostatin), dystroglycan 1, contactin 2, ephrin type a receptor 4, neural cell adhesion molecule L1 like protein, and contactin 1.

4. The method of claim 1 , wherein the estrogen receptor beta ligand is a compound having the structure of formula I:

5. The method of claim 1 , wherein the multiple sclerosis is relapsing-remitting multiple sclerosis, secondary-progressive multiple sclerosis, primary-progressive multiple sclerosis, or progressive-relapsing multiple sclerosis.

6. The method of claim 1 , wherein the method further comprises administering to the subject an immunotherapeutic agent.

7. The method of claim 6 , wherein the immunotherapeutic agent is selected from interferon-beta 1a, interferon-beta 1b, pegylated interferon-beta-1a, glatiramer acetate, natalizumab, mitoxantrone, fingolimod, teriflunomide, dimethyl fumarate, mycophenolate mofetil, paclitaxel, cyclosporine, corticosteroids, azathioprine, cyclophosphamide, methotrexate, cladribine, 4-aminopyridine, and tizanidine.

8. The method of claim 6 , wherein the immunotherapeutic agent is glatiramer acetate.

9. The method of claim 8 , wherein the multiple sclerosis is relapsing-remitting multiple sclerosis or secondary-progressive multiple sclerosis.

10. The method of claim 9 , wherein the subject is a woman.

11. The method of claim 1 , wherein, prior to administering the estrogen receptor beta ligand, the subject is receiving an immunotherapeutic agent or an anti-inflammatory agent.

12. The method of claim 11 , wherein the immunotherapeutic agent is selected from interferon-beta 1a, interferon-beta 1b, pegylated interferon-beta-1a, glatiramer acetate, natalizumab, mitoxantrone, fingolimod, teriflunomide, dimethyl fumarate, mycophenolate mofetil, paclitaxel, cyclosporine, corticosteroids, azathioprine, cyclophosphamide, methotrexate, cladribine, 4-aminopyridine, and tizanidine.

13. The method of claim 11 , wherein evaluating the subject's brain gray matter comprises the steps of:
assessing the change in the gray matter volume of the subject's cerebral cortex over a period of time; and
administering an effective amount of an estrogen receptor beta ligand to the subject conjointly with the immunotherapeutic agent or the anti-inflammatory agent if the gray matter volume of the cerebral cortex decreases by at least 0.3 percent between a first assessment and a second assessment about 6 months after the first assessment, by at least 0.6 percent between a first assessment and a second assessment about one year after the first assessment, or by at least 1.0 percent between a first assessment and a second assessment about two years after the first assessment.

14. The method of claim 13 , wherein the first assessment is performed before, at the same time as, or at about the same time as the first time the immunotherapeutic therapeutic agent or anti-inflammatory agent is administered.

15. The method of claim 13 , wherein the second assessment is performed at least about six months, at least about one year, at least about 18 months, or at least about two years after said first assessment.

16. The method of claim 1 , wherein after about 12 months of administration the subjects gray matter atrophy is less than 1.5%, less than 1.4%, less than 1.3%, less than 1.2%, less than 1.1%, less than 1.0%, less than 0.9%, less than 0.8%, less than 0.7%, less than 0.6%, or less than 0.5% as compared to the start of administration.

17. The method of claim 1 , wherein the subject's gray matter atrophy is reduced by 3.5% as compared to a subject who has not been administered the estrogen receptor beta ligand.

18. The method of claim 1 , wherein the estrogen receptor beta ligand is diarylpropionitrile.

19. The method of claim 1 , wherein the multiple sclerosis is relapsing-remitting multiple sclerosis or secondary-progressive multiple sclerosis.

20. The method of claim 1 , wherein the subject is a woman.

Assignees

• Univ California

Inventors

• Voskuhl Rhonda R

Classifications

• A61K31/05 Primary

  Phenols {(cannabinoids A61K31/658)} · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K31/137

  Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• C07D307/93

  condensed with a ring other than six-membered · CPC title